// App-Quantinova.ai

1482 : Anti-GPC3 TRAB, a first-in-class T cell-redirecting bispecific antibody targeting glypican-3 with potent in vitro and in vivo antitumor efficacy against solid tumors

Researchers

Presenter

  • Yasuko Kinoshita

Principal Investigators

  • Takahiro Ishiguro

  • Yuji Sano

  • Yumiko Azuma

  • Toshiaki Tsunenari

  • Natsuki Ono

  • Yoko Kayukawa

  • Otoya Ueda

  • Naoko A. Wada

  • Hiroshi Hino

  • Koichi Jishage

  • Hirotake Shiraiwa

  • Mika Kamata-Sakurai

  • Junichi Nezu

  • Mika Endo

Medical Centers

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Chugai Pharmabody Research Pte. Ltd., Singapore.

Locations

  • Japan

  • Singapore

Companies

  • Chugai Pharmaceutica

  • Chugai Pharmabody Re

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

  • Lung Cancer

  • Ovarian clear cell carcinoma

  • Squamous cell carcinoma

  • Gastric Cancer

  • Clear-cell adenocarcinoma

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 25

  • Cluster of Differentiation 2AP

  • Cluster of differentiation 69

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • Interleukin 4

  • Interleukin 6

  • Interleukin-2

  • Tumor necrosis factor

  • T-cell receptor

Drug/Treatment

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved